Provided are methods for preventing and/or reducing weight gain in subjects. In some embodiments, the methods include administering an effective amount of a composition that includes a long chain fatty acid of at least 22 carbons and/or a derivative thereof to prevent and/or reduce weight gain in the subject. In some embodiments, the long chain fatty acid is a monounsaturated omega 9 fatty acid, which in some embodiments is nervonic acid or a derivative thereof. Also provided are methods for preventing and/or reducing the development of obesity in subjects, for inhibiting reduction of very-long chain sphingolipids in subjects, for increasing content of one or more ceramides while simultaneously decreasing content of one or more C20-C26 ceramides in subjects, and for reducing blood glucose levels resulting from consumption of high fat diets in subjects.

In one aspect, methods for modulating an inflammatory response are provided comprising administration to a cell or organism a monoacetyl diacylglycerol compound.

In one aspect, methods for modulating an inflammatory response are provided comprising administration to a cell or organism a monoacetyl diacylglycerol compound.

Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.

Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.

Use of a compound having the formula (1) (2) (3) (4) or combinations thereof, for providing a source of butyrate with improved organoleptic properties wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently a long chain fatty acid having between 16 and 20 carbons for use in recovery from antibiotic mediated gut microbiota disturbance and/or preventing and/or treating gastrointestinal infections.

Use of a compound having the formula (1) (2) (3) (4) or combinations thereof, for providing a source of butyrate with improved organoleptic properties wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently a long chain fatty acid having between 16 and 20 carbons for use in recovery from antibiotic mediated gut microbiota disturbance and/or preventing and/or treating gastrointestinal infections.

This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.

This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.

The present invention provides a highly safe non-lamellar liquid crystal-forming composition. The present invention relates to a non-lamellar liquid crystal-forming composition comprising a phospholipid and an amphipathic compound represented by the following general formula (I), wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes the integer 1 or 2, m denotes the integer 1 or 2, and R denotes a hydrophilic group having one or more hydroxyl groups, and wherein the composition has an increased biocompatibility by the phospholipid.

##STR00001##